QuaterWatch: 1,000 + deaths –>Digoxin / Suicide/ Violence –>Chantix
The latest QuarterWatch report (May 7, 2009) by the Institute for Safe Medication Practices (ISMP) found the following disturbing trends during the third Quarter of 2008:
The latest QuarterWatch report (May 7, 2009) by the Institute for Safe Medication Practices (ISMP) found the following disturbing trends during the third Quarter of 2008:
In its response to Sen. Grassley’s probe, The National Alliance on Mental Illness (NAMI) acknowledges that a majority of its funds over the last five years, 56% on average, have come from drug corporations.
Merck is reported to have created a fake "peer-reviewed" journal to present favorable data that made its potentially fatal drugs–Fosamax and Vioxx–look good.
The Patriot Ledger reports that Rebecca Riley’s psychiatrist, Dr. Kayoko Kifuji, is under criminal investigation by a grand jury.
“Every failure-to-warn case against a drug company has been affected by Wyeth”
The Hill , a newspaper covering congressional news, reports: "Sen. Chuck Grassley (Iowa) is considering leaving his powerful post as senior Republican on the Finance Committee so that he can become the highest-ranking Republican on the Judiciary panel. To avoid a dramatic shake-up, Grassley is hoping to strike a deal with Sen. Jeff Sessions (R-Ala.)…
The FDA is sliding rapidly down the slippery slope, abandoning widely accepted, international ethical research standards articulated in the internationally accepted, Declaration of Helsinki–to facilitate commercial medical experiments.
AHRP proposes a multi-disciplinary team of independent scientists to review ALL of Dr. Joseph Biederman’s publications and supporting documents, including: research protocols, consent forms, and the original (of course, anonymized) data sets with associated code books for all pediatric studies.
"We’ve known this drug is a bad actor for a long time." Now it’s confirmed exposure to Depakote (valproate) in utero lowers children’s intelligence.
The FDA expanded approval process for toxic drugs is unaffected by evidence uncovered by the US Justice Department showing the studies to be flawed, if not fraudulent.
April 14: the FDA announced that Coast IRB "has agreed to voluntarily halt some aspects of its clinical trial oversight operations due to serious concerns about the company’s ability to protect human subjects participating in clinical trials."
The results suggest that the truth may have escaped the usual exclusion criteria. Underlying the commercial success of the new antipsychotics is evidence (usually suppressed) showing that these drugs are both harmful and ineffective even for their approved use.